Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

API Supplier Qualification: Hidden GMP Gaps We Found During a Client Assessment

Pharmaceutical companies increasingly need alternative API suppliers because of supply disruptions, cost pressures, and portfolio growth.

However, API supplier qualification now requires more than GMP certificates and audit reports. Companies must also assess synthesis routes, impurities, nitrosamine and NDSRI risks, analytical capability, data integrity, and drug-product impact.

Therefore, QA, QC, RA, MSAT, procurement, process chemistry, and toxicology teams must evaluate the supplier together. Our team reviewed these areas, identified key risks, and defined the actions required for supplier approval.

Challenges Faced

A detailed GAP analysis in Quality Management Systems is essential for identifying process deficiencies effectively.
  • Regulatory Scrutiny: Supplier changes may create new nitrosamine or NDSRI risks and require scientific justification.
  • Limited Scope: GMP records alone are insufficient; teams must review synthesis, impurities, methods, and drug-product risks.
  • Incomplete Synthesis Data: Review solvents, reagents, catalysts, amines, nitrites, and intermediates. One DMF-to-DMAc change created an NDSRI and caused a seven-month delay.
  • Impurity Risks: Assess known and unspecified impurities ≥0.05%, amine precursors, and nitrosation-sensitive structures.
  • Recycled Materials: Recycled solvents may introduce hydrazine or diazolide risks; one case caused a global recall.
  • Drug-Product Impact: Assess excipients, granulation, testing, and acceptable intakes. One interaction caused two batch rejections and six months of testing.
  • Regulatory Variation: A new impurity profile may require Type IB or II variation and delay launch.
  • Unclear Responsibilities: Weak ownership may leave assessments, CAPAs, tests, and regulatory actions incomplete.

Zamann Pharma Support’s Approach

  • Cross-Functional Setup: Zamann involved quality, regulatory, analytical, manufacturing, sourcing, and toxicology teams.
  • Assessment Scope: The review covered synthesis, impurities, nitrosamine, NDSRI, diazolide, materials, packaging, drug-product impact, GMP, data integrity, and laboratory capability.
  • Synthesis Review: The team assessed process materials, conditions, amines, nitrite sources, catalysts, and recycled solvents.
  • Impurity Assessment: The review covered known and unspecified impurities above 0.05%, batch data, stability, and analytical methods.
  • Nitrosamine and NDSRI Review: The team evaluated formation pathways, CPCA categories, acceptable intakes, NOx-rich reagents, and test results.
  • Supplier Data Gaps: When supplier data was insufficient, the company completed the assessment independently.
  • Diazolide Risk Review: The team assessed recycled solvents, hydrazine sources, and possible diazolide pathways.
  • Acceptable Intake: The assessment used EMA limits, FDA interim limits, supplier data, and toxicological read-across.
  • Drug-Product Impact: The team identified required testing, specification changes, and regulatory variations.
  • GMP and Data Integrity: The review covered certificates, audits, CAPAs, change control, data integrity, stability chambers, and laboratory competence.
  • Expert Report: The final report defined risks, testing, acceptable intakes, CAPAs, market actions, and approval conditions.
  • Operational Tracking: A central tracker recorded supplier status, impurity reviews, testing needs, AI decisions, and regulatory actions.

Results Achieved

  • Regulatory Readiness: The company gained a scientifically justified qualification package.
  • Risk Control: The assessment identified nitrosamine precursors, vulnerable impurities, and drug-product interactions early.
  • Supplier Decisions: The report supported approval, conditional approval, or rejection.
  • Lower Delay Risk: Early planning reduced rejected batches, recalls, authority questions, and launch delays.
  • Improved Coordination: The workflow clarified responsibilities across quality, regulatory, technical, and sourcing teams.
  • Faster Diversification: The process supported quicker assessment of alternative suppliers.
  • Business Continuity: The approach reduced supply disruption, product suspension, and market withdrawal risks.
Laboratory
Services
Pharmaceutical team managing GMP Quality Management System (QMS) activities, reviewing change control records, CAPA documentation, deviation reports, and audit readiness data in a regulated manufacturing environment.
Services

Quality Management System

We work with pharmaceutical teams to design, implement, and run effective Quality Management Systems, covering change control, CAPA, deviations, and audits to support consistent GMP compliance.

Read More

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

FAQ

1. Can a new API supplier create an NDSRI risk even when the final API contains no residual amine?

Yes. An upstream amine precursor may remain at trace levels or interact with nitrite during drug-product manufacturing. Therefore, the assessment must review the complete synthesis route, intermediates, impurity profile, and finished-product process.

 

2. Should unspecified API impurities at or above 0.05% enter the nitrosamine risk assessment?

Yes. An unspecified impurity may contain an amine or another structure vulnerable to nitrosation. Consequently, the qualification team should identify and assess these impurities instead of relying only on the API specification limits.

3. When can an API supplier change require a regulatory variation?

A change may require a variation when the new supplier introduces a different synthesis route, impurity profile, control strategy, testing requirement, or drug-product risk. The company must assess the applicable market requirements before completing the supplier switch.